1. Search Result
Search Result
Results for "

B7-H1/PD-L1 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

216

Inhibitors & Agonists

4

Screening Libraries

21

Peptides

64

Inhibitory Antibodies

5

Natural
Products

22

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2474

    PD-1/PD-L1 Cancer
    Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 [1].
    Human <em>PD-L1</em> inhibitor I
  • HY-P2478

    PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 [1].
    Human <em>PD-L1</em> inhibitor V
  • HY-P2470

    PD-1/PD-L1 Cancer
    Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity [1].
    Human <em>PD-L1</em> inhibitor II
  • HY-P2478A

    PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 [1].
    Human <em>PD-L1</em> inhibitor V TFA
  • HY-P2564

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
    Human <em>PD-L1</em> inhibitor III
  • HY-P2477

    PD-1/PD-L1 Inflammation/Immunology
    Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 [1].
    Human <em>PD-L1</em> inhibitor IV
  • HY-P5276

    PD-1/PD-L1 Cancer
    Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce PD-L1 antibody production [1].
    Human membrane-bound <em>PD-L1</em> polypeptide
  • HY-P99145

    PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-L1 Antibody is an anti-mouse PD-L1 IgG2b antibody inhibitor derived from host rat.
    Anti-Mouse <em>PD-L1</em> Antibody (10F.9G2)
  • HY-149830

    PD-1/PD-L1 Cancer
    PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research [1].
    <em>PD-L1</em>-IN-2
  • HY-134884

    PD-1/PD-L1-IN-8

    PD-1/PD-L1 Cancer
    INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research [1].
    INCB086550
  • HY-145774

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-23
  • HY-154869

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-34
  • HY-P990014

    IMC-001; STI-3031

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) humanized monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic [1].
    Danburstotug
  • HY-155101

    PD-1/PD-L1 Cancer
    PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research [1].
    <em>PD-L1</em>-IN-3
  • HY-139781

    PD-1/PD-L1 Cancer
    PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells [1].
    <em>PD-L1</em>-IN-<em>1</em>
  • HY-152240

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-29
  • HY-103048

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN 3
  • HY-103048A

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN 3 TFA
  • HY-144258

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-14
  • HY-144447

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of PD-1/PD-L1 with an IC50 value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-17
  • HY-155959

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-33
  • HY-144442

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of PD-1/PD-L1 with an IC50 value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-15
  • HY-144443

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of PD-1/PD-L1 with an IC50 value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-16
  • HY-132192

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-9
  • HY-132192A

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-9 hydrochloride
  • HY-116274

    PD-1/PD-L1 Cancer
    BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 [1].
    BMS-8
  • HY-144746

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-26
  • HY-129172

    PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    PD-1/PD-L1-IN 5 TFA is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN 5 TFA
  • HY-153064

    PD-1/PD-L1-IN-30

    PD-1/PD-L1 Cancer
    MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor, with an IC50 value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases [1].
    MAX-10181
  • HY-131183

    PROTACs PD-1/PD-L1 Inflammation/Immunology
    PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner [1].
    PROTAC PD-<em>1</em>/<em>PD-L1</em> degrader-<em>1</em>
  • HY-156150

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death [1].
    CYP51/<em>PD-L1</em>-IN-2
  • HY-156151

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death [1].
    CYP51/<em>PD-L1</em>-IN-3
  • HY-156149

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death [1].
    CYP51/<em>PD-L1</em>-IN-<em>1</em>
  • HY-138407

    GS-4224; PD-1/PD-L1-IN 7

    PD-1/PD-L1 HBV Infection Cancer
    Evixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions [1].
    Evixapodlin
  • HY-P99833

    CK-301; TG-1501

    PD-1/PD-L1 Cancer
    Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells [1].
    Cosibelimab
  • HY-P99633

    BGB-A333

    PD-1/PD-L1 Apoptosis Cancer
    Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity [1].
    Garivulimab
  • HY-P99944

    Retlirafusp alfa

    PD-1/PD-L1 TGF-β Receptor Cancer
    SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research [1].
    SHR-1701
  • HY-120402

    PD-1/PD-L1 Inflammation/Immunology
    BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM. BMS-200 can induce dimerization of PD-L1 [1].
    BMS-200
  • HY-150879

    PD-1/PD-L1 Ligands for Target Protein for PROTAC Cancer
    BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor. BMS-37 can be used as PD-L1 ligand to synthesize PROTAC molecules [1].
    BMS-37
  • HY-P99544

    HBM-9167; KL-A167

    PD-1/PD-L1 Cancer
    Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1] .
    Tagitanlimab
  • HY-108730
    Avelumab
    5+ Cited Publications

    Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
    Avelumab
  • HY-156850

    HDAC Cancer
    ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8 T cells, and shows anti-tumor activity [1].
    ITF 3756
  • HY-P1812

    NP-12

    PD-1/PD-L1 Cancer
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) [1].
    AUNP-12
  • HY-P1812A

    NP-12 TFA

    PD-1/PD-L1 Cancer
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) [1].
    AUNP-12 TFA
  • HY-P99422

    SHR-1316

    PD-1/PD-L1 Apoptosis Cancer
    Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) [1] .
    Adebrelimab
  • HY-108730A
    Avelumab (anti-PD-L1)
    5+ Cited Publications

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity [1].
    Avelumab (anti-<em>PD-L1</em>)
  • HY-P9972

    PDR001

    PD-1/PD-L1 Cancer
    Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) [1].
    Spartalizumab
  • HY-130625

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN 6
  • HY-N12537

    PD-1/PD-L1 Cancer
    PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 + T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-38
  • HY-145769

    PD-1/PD-L1 Cancer
    N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use 99mTc-labelled complexes 99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method [1].
    N2S2-CBMBC
  • HY-129172A

    PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN 5
  • HY-145770

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC50 of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-19
  • HY-145771

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-20
  • HY-145772

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC50 of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-21
  • HY-145773

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC50 of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-22
  • HY-145768

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC50 of 1.054 μM. Antitumor Activity [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-18
  • HY-149213

    Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research [1].
    LSD<em>1</em>-IN-24
  • HY-143305

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-25
  • HY-163041

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-36
  • HY-146740

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 + T cells and reduces T cell exhaustion [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-27
  • HY-144649

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC50 value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-24
  • HY-P99475

    MSB-2311

    PD-1/PD-L1 Cancer
    Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research [1].
    Betifisolimab
  • HY-149617

    Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target (CYP51/PD-L1) inhibitor, with IC50 values of 0.17 and 0.021 μM, respectively. CYP51/PD-L1-IN-4 exhibits excellent antifungal and antidrug-resistant fungal activity in vitro. CYP51/PD-L1-IN-4 can be used for fungal infections research [1].
    CYP51/<em>PD-L1</em>-IN-4
  • HY-148305

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of PD-1/PD-L1 signaling pathway (IC50=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-28
  • HY-149356

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-31
  • HY-131347

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-NP19
  • HY-132202

    PD-1/PD-L1 Apoptosis Cancer
    PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-10
  • HY-145239

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-13
  • HY-155740

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability [1].
    PD-<em>1</em>/<em>PD-L1</em>-IN-32
  • HY-P99048

    IBI308

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [1].
    Sintilimab
  • HY-W457085

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 intermediate-2 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-<em>1</em>/<em>PD-L1</em>-IN-29 intermediate-2
  • HY-48934

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 intermediate-1 is an intermediate of PD-1/PD-L1 inhibitors and can be used to synthesize Antibody-Drug Conjugates (ADCs).
    PD-<em>1</em>/<em>PD-L1</em>-IN-29 intermediate-<em>1</em>
  • HY-P99613

    MK-4280

    LAG-3 Cancer
    Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) [1] .
    Favezelimab
  • HY-P3440

    PD-1/PD-L1 Cancer
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression [1].
    WL12
  • HY-P99115

    ASC 22; KN 035

    PD-1/PD-L1 Cancer
    Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors [1] .
    Envafolimab
  • HY-N12537A

    Aryl Hydrocarbon Receptor PD-1/PD-L1 Cancer
    (2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 +T cells and inhibits the signal transduction of PD-1/PD-L1 [1].
    (2R,3S)-PD-<em>1</em>/<em>PD-L1</em>-IN-38
  • HY-P99723

    BCD-135

    PD-1/PD-L1 Cancer
    Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) [1].
    Manelimab
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    2 Publications Verification

    PD-1/PD-L1 Cancer
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 [1] .
    Pembrolizumab (anti-PD-<em>1</em>)
  • HY-142221

    PD-1/PD-L1 Cancer
    ARB-272572 is a potent small-molecule PD-L1 inhibitor with an IC50 value of 400 pM.
    ARB-272572
  • HY-P99799

    CX-072

    PD-1/PD-L1 Cancer
    Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity [1].
    Pacmilimab
  • HY-N0242
    Fraxinellone
    1 Publications Verification

    PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT Inflammation/Immunology Cancer
    Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 [1].
    Fraxinellone
  • HY-P9919
    Durvalumab
    5 Publications Verification

    MEDI 4736

    PD-1/PD-L1 Cancer
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody [1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
    Durvalumab
  • HY-19991
    BMS-1
    15+ Cited Publications

    PD-1/PD-L1 inhibitor 1

    PD-1/PD-L1 Apoptosis Inflammation/Immunology Cancer
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1] .
    BMS-<em>1</em>
  • HY-101058

    PD-1/PD-L1 Inflammation/Immunology
    PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator [1].
    PD<em>1</em>-<em>PDL</em><em>1</em>-IN <em>1</em>
  • HY-P9904
    Atezolizumab
    15+ Cited Publications

    MPDL3280A

    PD-1/PD-L1 Apoptosis Autophagy Cancer
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
    Atezolizumab
  • HY-P99641

    PD-1/PD-L1 Cancer
    Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 [1].
    Gilvetmab
  • HY-101058A

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator [1].
    PD<em>1</em>-<em>PDL</em><em>1</em>-IN <em>1</em> TFA
  • HY-19745
    BMS-202
    10+ Cited Publications

    PD-1/PD-L1 Apoptosis Cancer
    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity [1] .
    BMS-202
  • HY-102011

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
    BMS-1166
  • HY-102011A

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
    BMS-1166 hydrochloride
  • HY-P99610

    BI-754091

    PD-1/PD-L1 Cancer
    Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo [1].
    Ezabenlimab
  • HY-P9971
    Camrelizumab
    1 Publications Verification

    SHR-1210

    PD-1/PD-L1 Cancer
    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al [1] .
    Camrelizumab
  • HY-P3139

    PD-1/PD-L1 Cancer
    TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function [1].
    TPP-<em>1</em>
  • HY-P99345

    TSR-042

    PD-1/PD-L1 Cancer
    Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively [1].
    Dostarlimab
  • HY-101093
    CA-170
    1 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes [1] .
    CA-170
  • HY-P3139A

    PD-1/PD-L1 Cancer
    TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function [1].
    TPP-<em>1</em> TFA
  • HY-128605

    PD-1/PD-L1 Cancer
    PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM [1].
    PD-<em>1</em>-IN-22
  • HY-P99499

    JNJ 63723283; JNJ 3283

    PD-1/PD-L1 Interleukin Related TNF Receptor Cancer
    Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo [1].
    Cetrelimab
  • HY-P99419

    GEN1046

    PD-1/PD-L1 Cancer
    Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer [1] .
    Acasunlimab
  • HY-W771599

    APY69

    PD-1/PD-L1 Cancer
    ASC-69 (APY69)is a potent and promising?PD-1/PD-L1 small-molecule inhibitor [1].
    ASC-69
  • HY-P3143A

    PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs [1].
    BMSpep-57 hydrochloride
  • HY-157569

    PD-1/PD-L1 Cancer
    PD1-PDL1-IN 2 (ZE132) is a potent and selective PD-1/PD-L1 inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β [1].
    PD<em>1</em>-<em>PDL</em><em>1</em>-IN 2
  • HY-P3143

    PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs [1].
    BMSpep-57
  • HY-155580

    Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
    MAO A/HSP90-IN-2
  • HY-P99114

    PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research [1].
    Sugemalimab
  • HY-P99109

    GLS-010; AB-122; WBP-3055

    PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma [1] .
    Zimberelimab
  • HY-145288

    Apoptosis Cancer
    Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues [1].
    Antitumor agent-36
  • HY-145289

    Apoptosis Cancer
    Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues [1].
    Antitumor agent-37
  • HY-145240

    Eukaryotic Initiation Factor (eIF) Infection Cancer
    eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) [1].
    eIF4E-IN-<em>1</em>
  • HY-144501

    Toll-like Receptor (TLR) PD-1/PD-L1 Inflammation/Immunology Cancer
    D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 [1].
    D18
  • HY-155577

    Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC50 value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research [1].
    MAO A/HSP90-IN-<em>1</em>
  • HY-155681

    PD-1/PD-L1 Monoamine Oxidase Cancer
    SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) [1].
    SWS<em>1</em>
  • HY-126147

    HDAC Cancer
    J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 [1].
    J22352
  • HY-N0596

    20(R)-Panaxadiol

    PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT Cancer
    Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities [1] .
    Panaxadiol
  • HY-115885

    HDAC Inflammation/Immunology Cancer
    XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma [1].
    XP5
  • HY-P99963

    HS636

    PD-1/PD-L1 Cancer
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment [1].
    Sudubrilimab
  • HY-138139A

    T785 hydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology
    AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 [1]. AXC-715, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 hydrochloride
  • HY-138139B

    T785 trihydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology
    AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 [1]. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 trihydrochloride
  • HY-155115

    Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer [1].
    LSD<em>1</em>-IN-27
  • HY-100022
    Tomivosertib
    5 Publications Verification

    eFT508

    MNK PD-1/PD-L1 Cancer
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines [1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
    Tomivosertib
  • HY-P990088

    VEGFR PD-1/PD-L1 Cardiovascular Disease
    Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor [1].
    Sotiburafusp alfa
  • HY-153543

    Toll-like Receptor (TLR) Cancer
    TLR7/8 agonist 8 (compound 24m) is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1 blockade [1].
    TLR7/8 agonist 8
  • HY-16141
    Cilengitide
    Maximum Cited Publications
    38 Publications Verification

    EMD 121974

    Integrin Autophagy Apoptosis STAT PD-1/PD-L1 Cancer
    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers [1] .
    Cilengitide
  • HY-146293

    HDAC HSP Cancer
    HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of HDAC6 and HSP90, with IC50 values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice [1].
    HDAC6/HSP90-IN-<em>1</em>
  • HY-128679

    IKK Cancer
    TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC50 values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to PD-1 and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity [1].
    TBK<em>1</em>/IKKε-IN-5
  • HY-P99457

    AGEN2034

    PD-1/PD-L1 Inflammation/Immunology
    Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .
    Balstilimab
  • HY-P99106

    PD-1/PD-L1 Cancer
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .
    Acrixolimab
  • HY-P9997

    ANB030

    PD-1/PD-L1 Cancer
    Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
    Rosnilimab
  • HY-P99144
    Anti-Mouse PD-1 Antibody (RMP1-14)
    1 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology
    Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG1 antibody inhibitor.
    Anti-Mouse PD-<em>1</em> Antibody (RMP<em>1</em>-14)
  • HY-P99679

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].
    Izuralimab
  • HY-P99449

    P3x22914G4

    PD-1/PD-L1 Inflammation/Immunology
    Atorolimumab (P3x22914G4) is a monoclonal antibody used for immunotherapies targeting programmed death-1 (PD-1) .
    Atorolimumab
  • HY-P99639

    APL-501; CBT-501; GB-226

    PD-1/PD-L1 Cancer
    Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer [1].
    Geptanolimab
  • HY-101454
    SR0987
    2 Publications Verification

    ROR Inflammation/Immunology Cancer
    SR0987, a SR1078 analog, is a RORγt agonist, with an EC50 of 800 nM. SR0987 increases IL17 expression while repressing the expression of PD-1 [1].
    SR0987
  • HY-P99203

    PD-1/PD-L1 Cancer
    Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research [1] .
    Cemiplimab
  • HY-P99895

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity [1].
    Rulonilimab
  • HY-131386A

    Target Protein Ligand-Linker Conjugates Cancer
    BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM [1].
    BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
  • HY-131386

    Target Protein Ligand-Linker Conjugates Cancer
    BMS-1166-N-piperidine-CO-N-piperazine incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM [1].
    BMS-1166-N-piperidine-CO-N-piperazine
  • HY-P9978

    PD-1/PD-L1 Cancer
    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma [1].
    Toripalimab
  • HY-P99166

    PD-1/PD-L1 CTLA-4 Inflammation/Immunology
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation [1].
    Vudalimab
  • HY-131187

    Ligands for Target Protein for PROTAC Cancer
    BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1 [1]. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166-N-piperidine-COOH
  • HY-P4072

    PD-1/PD-L1 Cancer
    (D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy [1].
    (D)-PPA <em>1</em>
  • HY-132559S

    Isotope-Labeled Compounds Others
    PD-166285-d4 is the deuterium labeled PD-166285[1].
    PD-166285-d4
  • HY-P4072A

    PD-1/PD-L1 Cancer
    (D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy [1].
    (D)-PPA <em>1</em> TFA
  • HY-134886

    PD-1/PD-L1 Cancer
    PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor [1].
    PD-<em>1</em>-IN-24
  • HY-Y0588

    L-Cbz-Proline

    Others Others
    Carbobenzoxyproline (L-Cbz-Proline) is an inhibitor of prolidase. Carbobenzoxyproline can be used for prolidase deficiency (PD) research .
    Carbobenzoxyproline
  • HY-P99618

    IBI-315; BH2950

    EGFR PD-1/PD-L1 Inflammation/Immunology Cancer
    Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity [1].
    Fidasimtamab
  • HY-P99887

    JTX-4014

    PD-1/PD-L1 Cancer
    Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor [1].
    Pimivalimab
  • HY-P99957

    AMG-404

    PD-1/PD-L1 Cancer
    Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer [1].
    Zeluvalimab
  • HY-P990035

    PD-1/PD-L1 Cancer
    Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, derived from mice [1].
    Benmelstobart
  • HY-P99387

    LAG-3 Cancer
    TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity [1].
    TSR-033
  • HY-P99573

    MGD-013

    LAG-3 Inflammation/Immunology Cancer
    Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [1] .
    Tebotelimab
  • HY-P990029

    PD-1/PD-L1 Infection Cancer
    Eciskafusp alfa is a programmed cell death 1 (PDCD1, best known as PD-1) cis-targeted IL2v immunocytokine. Eciskafusp alfa preferentially targets antigen-specific stem-like PD-1+ TCF-1+ CD8+ T cells and differentiates them towards a novel population of better effectors. Eciskafusp alfa can be used for the research of cancer and chronic infections [1].
    Eciskafusp alfa
  • HY-P9902
    Pembrolizumab
    5+ Cited Publications

    MK-3475; Lambrolizumab

    PD-1/PD-L1 Cancer
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    Pembrolizumab
  • HY-P99619

    SCT-I10A

    PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research [1].
    Finotonlimab
  • HY-157055

    PD-1/PD-L1 Cancer
    PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ T cell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth [1].
    PD-<em>1</em>-IN-25
  • HY-P9903
    Nivolumab
    10+ Cited Publications

    BMS-936558; ONO-4538; MDX-1106

    PD-1/PD-L1 Cancer
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab
  • HY-P9996

    LY3434172

    PD-1/PD-L1 Cancer
    Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research [1] .
    Reozalimab
  • HY-155150

    LRRK2 PROTACs Cancer
    JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD)?research .
    JH-XII-03-02
  • HY-P99884

    PF-06801591

    PD-1/PD-L1 Others
    Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells [1].
    Sasanlimab
  • HY-P9993

    LY-3462817

    PD-1/PD-L1 Cancer
    Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis [1] .
    Peresolimab
  • HY-P99785

    HLX20

    PD-1/PD-L1 Cancer
    Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors [1].
    Opucolimab
  • HY-155847

    Phosphatase Cancer
    LYP-IN-3 (compound D34) is a selective inhibitor of Lymphoid-tyrosine phosphatase (LYP) (Ki=0.93 μM), and regulates T-cell receptor (TCR) signaling pathway in tumor progress. LYP-IN-3 activates T-cell and inhibits M2 macrophage polarization, but upregulates PD-1/PD-L1 expression. LYP-IN-3 can be leveraged with PD-1/PD-L1 inhibitor, for futher cancer immunotherapy [1].
    LYP-IN-3
  • HY-19745A

    PD-1/PD-L1 Cancer
    N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-1/PD-L1 interaction, mainly used for cancer treatment.
    N-deacetylated BMS-202
  • HY-P99100

    CTL-002

    PD-1/PD-L1 Cancer
    Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors [1].
    Visugromab
  • HY-30105

    PROTAC Linkers Cancer
    N-Boc-piperazine is a Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) [1].
    N-Boc-piperazine
  • HY-P9903A
    Nivolumab (anti-PD-1)
    10+ Cited Publications

    PD-1/PD-L1 Cancer
    Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer [1].
    Nivolumab (anti-PD-<em>1</em>)
  • HY-101097

    PD-1/PD-L1 Cancer
    PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM [1].
    PD-<em>1</em>-IN-17
  • HY-101097A

    PD-1/PD-L1 Cancer
    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM [1].
    PD-<em>1</em>-IN-17 TFA
  • HY-132212

    PD-1/PD-L1 Inflammation/Immunology Cancer
    LH1307 is a C2-symmetric inhibitor of PD-1/PD-L1 protein-protein interactions with a IC50 value of 3.0 μM and can be used in cancer studies [1].
    LH1307
  • HY-W004701

    PROTAC Linkers Cancer
    Br-C3-methyl ester is a Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) [1].
    Br-C3-methyl ester
  • HY-P990072

    PD-1/PD-L1 Cancer
    Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity [1].
    Lipustobart
  • HY-P99489

    ABBV 181; PR 1648817

    PD-1/PD-L1 Cancer
    Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function [1].
    Budigalimab
  • HY-P5041

    α-synuclein Neurological Disease
    α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .
    α-Synuclein (34-45) (human)
  • HY-132223

    PD-1/PD-L1 Inflammation/Immunology Cancer
    LH1306 is a C2-symmetric inhibitor of PD-1/PD-L1 protein-protein interaction (PPI), with an IC50 value of 25 nM. LH1306 can be used in anti-tumor research [1].
    LH1306
  • HY-50868
    Bafetinib
    5+ Cited Publications

    INNO-406; NS-187

    Bcr-Abl Src Apoptosis Cancer
    Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity [1] .
    Bafetinib
  • HY-131454
    SR-717
    5+ Cited Publications

    STING Inflammation/Immunology Cancer
    SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity [1].
    SR-717
  • HY-131454A

    STING Inflammation/Immunology Cancer
    SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity [1].
    SR-717 free acid
  • HY-112855

    LRRK2 Neurological Disease
    PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .
    PF-06454589
  • HY-155568

    Reactive Oxygen Species Apoptosis Neurological Disease Inflammation/Immunology
    Flo8 is a potent anti-inflammatory and antioxidant compound. Flo8 inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO) and suppresses neuronal apoptotic by inhibiting inflammatory and apoptotic signaling pathways. Flo8 can be used for Parkinson's Disease (PD) research .
    Anti-inflammatory agent 47
  • HY-P3342

    PD-1/PD-L1 Apoptosis Inflammation/Immunology
    [D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes [1].
    [D-Leu-4]-OB3
  • HY-153793

    DGK Cancer
    DGKζ-IN-1 (compound 9) is an inhibitor of DGKζ. DGKζ-IN-1 can be used for research in cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody [1].
    DGKζ-IN-<em>1</em>
  • HY-156573

    DGK Cancer
    DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor [1].
    DGKα&ζ-IN-<em>1</em>
  • HY-101093B

    PD-1/PD-L1 Cancer
    PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 [1].
    PD-<em>1</em>-IN-20
  • HY-136220

    Aryl Hydrocarbon Receptor Cancer
    AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1 [1].
    AHR antagonist 5
  • HY-P99714

    MGD019

    PD-1/PD-L1 CTLA-4 Cancer
    Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) [1] .
    Lorigerlimab
  • HY-120635

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM [1] .
    BMS-1001 hydrochloride
  • HY-124729

    ULK Autophagy Neurological Disease
    BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment .
    BL-918
  • HY-131186

    E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) [1].
    Pomalidomide-amido-C3-piperazine-N-Boc
  • HY-120647

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM [1] .
    BMS-1001
  • HY-131184

    PROTAC Linkers Inflammation/Immunology
    N-Boc-piperazine-C3-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-N-piperazine-C3-COOH can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183) [1].
    N-Boc-piperazine-C3-COOH
  • HY-P99594

    ZKAB001; STI-1014; STI-A1014

    PD-1/PD-L1 Cancer
    Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma [1] .
    Socazolimab
  • HY-155137

    Monoamine Oxidase Reactive Oxygen Species Neurological Disease
    CHBO4 is a potent, reversible, competitive, and selective hMAO-B inhibitor with an IC50 value of 0.031 μM in CHBO subseries and an Ki value of 0.010 ± 0.005 μM. CHBO4 reduce cell damage by scavenging intracellular reactive oxygen species (ROS). CHBO4 can be used for Parkinson's Disease (PD) research .
    CHBO4
  • HY-157400

    Monoamine Oxidase Neurological Disease
    hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC50 value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .
    hMAO-B-IN-7
  • HY-130642

    E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 .
    (S,R,S)-AHPC-Me-C10-Br
  • HY-P99052

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer [1].
    Tislelizumab
  • HY-110125

    CID 1261822

    GPR55 Neurological Disease
    ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
    ML-193
  • HY-132296

    FAK PROTACs Cancer
    GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
    GSK215
  • HY-149941

    Neurotensin Receptor Neurological Disease
    hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (Ki: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent [1].
    hNTS<em>1</em>R agonist-<em>1</em>
  • HY-P10091

    PD-1/PD-L1 Cancer
    CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell [1].
    CD24/Siglec-10 blocking peptide, CSBP
  • HY-N0460

    NF-κB Cancer
    1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.002 μM and binding energy of 1.50 Kcal/mol [1]. 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits PD-1/PD-L1 interact .
    <em>1</em>-Caffeoylquinic acid
  • HY-144497

    PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC Infection Cancer
    HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity [1].
    HE-S2
  • HY-P99687

    AMG 256

    PD-1/PD-L1 Cancer
    Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research [1] .
    Latikafusp
  • HY-151430

    Keap1-Nrf2 ERK Akt JNK Reactive Oxygen Species Neurological Disease
    Nrf2/HO-1 activator 1 (Compound 24) is a potent Nrf2/HO-1 activator, neuroprotective agent. Nrf2/HO-1 activator 1 shows neuroprotective and antioxidant activities. Nrf2/HO-1 activator 1 can be used in Parkinson's disease (PD) research .
    Nrf2/HO-<em>1</em> activator <em>1</em>
  • HY-163145

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .
    α-Synuclein inhibitor 11
  • HY-75502
    Rotigotine
    1 Publications Verification

    N-0923; (-)-N 0437

    Dopamine Receptor Adrenergic Receptor 5-HT Receptor Neurological Disease Endocrinology
    Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .
    Rotigotine
  • HY-152671

    Monoamine Oxidase Neurological Disease
    hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value and a Ki value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC50 value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .
    hMAO-B-IN-4
  • HY-153544

    Toll-like Receptor (TLR) Cancer
    TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy [1].
    TLR7/8 agonist 9
  • HY-156085

    PD-1/PD-L1 Cancer
    LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC50: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) [1].
    LP23
  • HY-138742

    MAP4K Cancer
    HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 [1].
    HPK<em>1</em>-IN-7
  • HY-155457

    Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence [1].
    Enpp-<em>1</em>-IN-19
  • HY-13488
    HG-10-102-01
    1 Publications Verification

    LRRK2 MNK Neurological Disease
    HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .
    HG-10-102-01
  • HY-16961
    Sitravatinib
    1 Publications Verification

    MGCD516; MG-516

    VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib
  • HY-16961A

    MGCD516 malate; MG-516 malate

    VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib malate
  • HY-155848

    Phosphatase Cancer
    LYP-IN-4 (compound D14) is a reversible and selective inhibitor of lymphotyrosine phosphatase (LYP) (Ki=1.34 μM, IC50=3.52μM). LYP-IN-4 inhibits LYP to regulate TCR signaling, up-regulates PD-1/PD-L1 expression, and enhance anti-tumor immunity. LYP-IN-4 activates T cells and inhibits M2 macrophage polarization, inhibits tumor growth in MC38 isogenic mouse models.
    LYP-IN-4
  • HY-149509

    α-synuclein Neurological Disease
    α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
    α-Synuclein inhibitor 9
  • HY-144088

    HPK1-IN-22

    MAP4K Inflammation/Immunology Cancer
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a + CD8 + T Cells, PD-1 +CD8 + T Cells, TIM-3 +CD8 + T Cells LAG3< sup>+CD8 + T Cellular immersion decreases.
    ZYF0033